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Summary:Metabolic syndrome is the commonest controllable precursor of cardiovascular and end stage renal diseases. 
While central obesity is recognized universally as its strongest component, there is the need for an accurate and affordable 
tool to screen for the presence of metabolic syndrome in every community.  The easiest and cheapest measures of obesity 
are the body mass index (BMI), waist circumference (WC) and waist to hip ratio (WHR). This study investigated the 
potential of BMI, WHR and WC in diagnosis of metabolic syndrome (MS) in Nigerian subjects.This cross sectional study 
involved three hundred and thirty eight apparently healthy adult Nigerians recruited within the University College Hospital 
and its environs were evaluated for the features of metabolic syndrome using the World Health Organisation and the NCEP 
ATP 111 criteria. BMI, WC, WHR, Blood Pressure, Fasting Lipid Profile and Fasting Plasma Glucose were measured in 
each participant. Correlation between BMI, WC, WHR and Blood Pressure, Fasting Lipid Profile and Fasting Plasma 
Glucose which are other components of MS was determined and empirical Receiver Operating Characteristics (ROC) 
analysis was used to evaluate each of them as predictors of MS. The prevalence of MS in the studied population was 
significantly higher (36.7%) using NCEP definition than (23.7%) using WHO definition (p<0.05). By both definitions, this 
prevalence was higher in females than in males (p<0.05). WC was positively correlated with FPG and TG (r=0.560 and 
0.436 respectively; P=0.000) in the NCEP category while WC was positively correlated with FPG, SBP and DBP (r=0.254, 
0.480, and 0.490 respectively; P>0.05) in the WHO category. ROC Analysis shows WC having the highest AUC (0.785) 
hence diagnoses MS more accurately than both BMI (0.733) and WHR (0.783) using in the NCEP ATP 111 criteria. The 
highest Area Under Curve (AUC) was observed in WHR (0.837) followed by WC (0.799) in the WHO category.  Both 
WC and WHR are shown to be good predictors of the presence of MS. It will be appropriate to incorporate WC 
measurement into routine general physical examination in our clinics.   
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The metabolic syndrome as defined by Fezeu et al, 
(2007) is a cluster of the most dangerous, inter-
related and often undiagnosed heart attack risk factors 
of metabolic origin. These include diabetes or raised 
fasting plasma glucose, abdominal obesity, high 
cholesterol and high blood pressure. First described 
by Reaven in the late 1940s, it became clearly defined 
as a clinical entity in the 1980s (Wannamethee et al, 
2005. Einhorn et al, 2003). In 1998, the World Health 
Organization (WHO) was the first organization to 
provide a definition of the metabolic syndrome. In 
response, the European Group for the Study of 
Insulin Resistance (EGIR) countered with a 
modification of the WHO definition (Balkau & 
Charles, 1999). In 2001, the National Cholesterol 
Education Program (NCEP) released its definition. 
Subsequently, the American Association of Clinical 
Endocrinologists (AACE) offered its views regarding 
the definition of the metabolic syndrome (Einhorn et 
al, 2003). The proliferation of definitions suggested 
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that a single unifying definition was desirable (Ford, 
2004). In the hope of accomplishing this task, the 
International Diabetes Federation (IDF) proposed a 
new definition of the metabolic syndrome in April 
2005. 
 While Insulin resistance has been the pivotal 
feature in the WHO criteria, waist circumference 
(WC) rather than body mass index (BMI) has been 
the differentiating aspect of MS definition in the 
NCEP ATP-III panel. The International Diabetes 
Federation (IDF) proposed a slight modification in 
the ATP-III definition in 2005 where presence of 
abdominal obesity was considered mandatory for MS 
diagnosis. 
 The main focus in this new definition is central 
obesity (IDF, 2005). To have the metabolic 
syndrome, a person must have central adiposity 
defined on the basis of waist circumference and two 
or more of the following four factors: elevated 
concentrations of triglycerides, reduced 
concentrations of HDL cholesterol, elevated blood 
pressure, and dysglycemia (Ford, 2004; IDF, 2005). 
According to the WHO, the diagnosis of MS is 
accomplished by finding at least 1 of the following: 
(i) Type 2 DM (ii) Impaired Fasting Glucose (iii) 
Insulin Resistance, plus at least 2 of the following: (i) 
Hypertension (ii) Obesity (iii) Hypertriglyceridaemia 
or low HDL and (iv) Microalbuminuria (Balkau& 
Charles, 1999).  Other components of MS which are 
not of diagnostic significance include 
hyperuricaemia, hypercoagulability and 
hyperleptinaemia (Zimmet et al, 2001).  
 It was estimated that around 20-25 percent of the 
world’s adult population have the metabolic 
syndrome and they are twice as likely to die from and 
three times as likely to have a heart attack or stroke 
compared with people without the syndrome. People 
with the metabolic syndrome also have four to five 
fold increased risk of developing type 2 diabetics 
compared to those without the syndrome and each 
year, 3.2 million people around the world die from 
complications associated with diabetes (UKPDS 
Group, 1996).  
 The ‘clustering’ of metabolic abnormalities that 
occur in the same individual appear to confer a 
substantial additional cardiovascular risk over and 
above the sum of the risk associated with each 
abnormality (Golden et al, 2002). The more 
components of the metabolic syndrome that are 
evident, the higher is the cardiovascular mortality rate 
(Hu et al, 2004). 
It was estimated that in 2003 for the 25 European 
Union countries the total direct healthcare costs of all 
diabetes in 20 to 79 year olds was up to 64.9 billion 
ID, the equivalent to 7.2 per cent of the total health 
expenditure for these countries (IDF, 2005.).The 
annual direct healthcare cost of diabetes worldwide 
for this age group is conservatively estimated to be as 
much as 286 billion ID, or even more (Hu 2004, IDF, 
2005). If diabetes prevalence continues to rise as 
anticipated, it is likely that this figure will increase to 
396 billion ID by 2025 (IDF, 2005.). This will mean 
an expenditure of up to 13 per cent of the world’s 
healthcare budget on diabetes care, with high 
prevalence countries spending up to 40 per cent of 
their budget (IDF & IASO, 2004). It is important to 
note that these estimates of burden on national 
healthcare systems are for type 2 diabetes only and do 
not, as yet, estimate the additional burden of CVD 
associated with metabolic syndrome where clinical 
diabetes is not yet present (IDF & IASO, 2004; IDF, 
2005).  
 The prevalence of metabolic syndrome in most 
sub-Saharan African countries, although thought to 
be low; is largely unknown except for Cameroon 
where the highest prevalence of 5.9% was reported in 
urban women using the WHO diagnostic criteria 
(Fezeu et al, 2007). However, a rising prevalence of 
obesity has been reported in some of these countries 
including Nigeria especially in sub-urban populations 
(Bakari et al, 2007). 
 Obesity noted to provide the key stimulus for 
insulin resistance and type 2 Diabetes in other parts 
of the world; is becoming more prevalent in Nigeria 
(Bakari et al, 2007). So is the prevalence of type 2 
diabetes and hypertension which are cardinal features 
of the so called ‘metabolic syndrome’. Both of these 
conditions often co-exist, and are amenable to simple 
measures of weight reduction, diet and physical 
exercise if diagnosed early.  
Obesity has surrogate markers in simple and 
inexpensive anthropometry which can be performed 
outside the hospital, in the village setting and in 
offices to identify people at risk for these disorders. 
There is then the need to embark on local studies of 
Nigerian to examine the efficacy of anthropometric 
indices in the diagnosis of these disorders. This study 
was therefore designed to investigate the association 
between waist circumference, waist to hip ratio, and 
body mass index in the diagnosis of metabolic 
syndrome in Nigerian subjects. 
 
MATERIALS AND METHODS 
 
Design:  This is a cross-sectional study conducted 
within the University of Ibadan, University College 
Hospital, Ibadan and their immediate environs. 
Subjects: These include apparently healthy, adult 
volunteers from hospital and University staff and 
students. Participants comprised all volunteers who 
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gave free informed consent among apparently 
healthy, adult (not less than 25 years old) members of 
staff, postgraduate students and retirees from the 
College of Medicine, University of Ibadan/University 
College Hospital Ibadan and from petty traders and 
artisans who live or have their shops in the immediate 
vicinities around the University of Ibadan and the 
University College Hospital, Ibadan. Ethical 
Approval for the study was sought and obtained from 
the joint ethical review committee of the University 
of Ibadan and the University College Hospital, 





(N is sample size, Z is 1.96, P is 
prevalence, Q is 1-P, and D is 0.05). Since the 
prevalence of MS in Nigeria is not known, 5.9%, the 
prevalence of MS in urban women in Cameroon 
which was the highest prevalence found in 
Cameroonian populations by Fezeu et al in 2007 was 
used in this calculation which yielded a minimum 
sample size of 85.3. Therefore, three hundred and 
thirty eight physically healthy adults who were not 
less than 25years were studied. 
Measurements: The rationale and research protocol 
of the study were explained to the participants and 
they signed an informed consent form. Thereafter, 
blood Pressure, Weight, Height, WC and hip 
circumference were measured. Family history of 
diabetes or hypertension and treatment for either or 
both conditions were taken and recorded in a 
questionnaire. They were then asked to fast overnight 
and come to the metabolic research ward the 
following morning for blood collection. Five 
milliliters (5mL) of blood was collected from each 
participant via the anti-cubital vein into lithium 
heparin bottle for the determination of fasting plasma 
lipids. 
Weight was measured to the nearest 0.1kg with a 
Tanita digital bathroom weighing scale (Model 
HD358 manufactured by Our Weigh, UK.) calibrated 
on a daily basis using standard weights while height 
was measured using a stadiometer calibrated in 
metres to the 0.01metre.  BMI was calculated from 
the weight and height using the standard formula. 
Both waist and hip circumferences were measured in 
centimeters to the nearest 0.5cm with a non stretch 
tape. WC was measured at a point midway between 
the iliac crest and the lower rib margin on both sides. 
HC was measured at the widest point of the buttocks. 
WHR was calculated by dividing the waist 
circumference by the hip circumference. 
BP was measured in those who are not on drug 
treatment for hypertension using mercury in glass 
sphygmomanometer following standard procedure. 
Three readings were taken at a sitting and the average 
was recorded as the subject’s BP. Diagnosis of 
metabolic syndrome was made based on the WHO 
and NCEP ATP 111 criteria. 
 FPG was determined from finger prick specimens 
using a glucometer (Accu-check®) based on the 
enzymatic, glucose oxidase method. FPG was not 
done in known diabetics who are on medications. The 
blood samples for lipid analysis were centrifuged, 
separated and store frozen at -20
0
C until analysis. All 
samples were analysed within a week of collection. 
Total and HDL-Cholesterol and Triglyceride were 
analysed using standard enzymatic methods using 
kits manufactured by DialabGmbh, Austria. LDL-
Cholesterol was calculated using the Friedwald’s 
formula (LDL Chol=Total Chol-HDL Chol-TG/5). 
Control samples supplied by the manufacturers were 
analysed with each assay batch for glucose, total 
cholesterol, HDL cholesterol and triglyceride. The 
results for all assays were within control limits. 
 
Interpretation  
 A FPG>110mg/dl (or treatment for type 2 
diabetes) was considered a positive criterion and a 
necessary condition in the diagnosis of metabolic 
syndrome by the WHO definition. 
 A systolic BP>140mmHg and/or diastolic 
BP>90mmHg or both (on drug treatment for 
hypertension) is considered another positive criterion 
by WHO. A systolic BP of 130mmHg and/or 
diastolic of 85 mmHg (on antihypertensive drug 
treatment) is considered a positive criterion by NCEP 
ATP 111.  
 A HDL<35mg/dl (men), HDL<39mg/dl (women) 
is a criterion by WHO. HDL<40mg/dl (men), 
HDL<50mg/dl satisfies same criterion by ATP 111  
 Triacylglycerol (TG)>150mg/dl in both sexes is 
considered another positive criterion by both 
definitions. 
 WHR>0.95 (men), WHR>0.8 (women) is a 
criterion by the WHO. 
 WC>102cm (men), WC>88cm (women) is a 
criterion by ATP 111. 
Both WHO and NCEP-ATP III criteria were applied 
in diagnosing MS in this study. The WHO requires 
the presence of the first criterion above with any 
other two WHO criteria for the diagnosis of MS. The 
presence of any three of the ATP 111 criteria suffices 
for the diagnosis of MS using ATP 111 definition. 
 
Statistical Analysis 
Statistical Package for Social Sciences (SPSS) 15 was 
the software used for the data analysis. Overall age 
range was reported as mean ± standard deviations. 
Then, the ages were grouped into five categories 
(tables 3&4) and the frequencies of MS in both sexes 
were determined for the different age groups.  
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Correlation profile analysis was used to examine the 
correlations between obesity indices (BMI, WHR and 
WC) and major diagnostic components of MS. These 
indices were also compared in their abilities to 
correctly diagnose MS in both WHO & NCEP ATP 
111 diagnostic categories using Receiver Operating 
Characteristic (ROC) curves. Statistical significance 




A total of 338 subjects comprising 144 males and 194 
females aged between 25 and 73years 
(47.4years±25.4years) participated in the study. The 
overall prevalence of MS was higher in females than 
in males by both definitions (Table 1) 26.4% in males 
and 86(44.3%) females have metabolic syndrome by 
the NCEP-ATP III standard; while 26 (18%) males 
and 54 (27.8%) females have metabolic syndrome by 
the WHO standard (Tables 1). The proportion of 
participants with metabolic syndrome in females are 
higher than in males except for those below 35 years 
of age in the WHO group and those older than 
65years in the NCEP ATP 111 group (Tables 4&5). 
MS prevalence was higher in males than in females 
with positive WC criterion in both groups. A total of 
26 males and 98 females have WCs >102cm and 
88cm for males and females respectively out of 
which 22 males and 78 females have MS in the 
NCEP diagnostic category (p>0.05). In the WHO 
category, 18 out of 26 males and 48 out of 98 females 
have MS (Tables 2 & 3).  
 A total of 58 males and 148 females satisfy the 
WHO obesity criterion for the diagnosis of MS. Out 
of these, 32 males and 84 females have MS in the 
NCEP diagnostic category while 26 males and 30 
females have MS in the WHO diagnostic category. 
Among the overweight (BMI>25<30) totaling 140, 
56 (40%) in the NCEP category and 34 (24.3%) in 
the WHO have MS while among the obese (BMI≥30) 
comprising a total of 58 participants, 44 (75.9%) and 
36 (62.1%) have MS in the NCEP and WHO 
categories respectively (see tables 2 and 3). 
 
Table 1:  
Prevalence of MS among Adult Nigerian subjects using both WHO and NCEP ATP III criteria 






























Table 2:  
Physical and Biochemical characteristics of adult Nigerian subjects with or without MS (diagnosed by the NCEP-ATP III 
criteria 
















Male > 102 
Female >88 
Male > 0.95 
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Table 3:  
Physical and biochemical characteristics of adult Nigerian subjects with or without MS (diagnosed by WHO criteria) 

















Female > 88 
Male > 0.95 





Sys > 140 
Dias > 90 
Male < 35 














































Table 4: Prevalence of Metabolic Syndrome by NCEP-criteria by Age 
































































Table 5: Prevalence of MS by WHO criteria by Age 
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Table 6: Correlation Profile of BMI, WHR and WC with other components of MS in adult Nigerian subjects 
















































sStatistically significant (P<0.05), SBP: Systolic BP, DBP: Diastolic BP, HDL: High Density lipoprotein, TG: Triglycerides, FPG: Fasting Plasma 
Glucose. 
 
Table 7: Areas under the curves for BMI, WHR and WC in ROC curves for MS 
 
Test Variable 
Area under the curve 











 Among participants with positive BP criteria 
totaling 178 and 169 in the NCEP and WHO groups 
respectively, 102 (57.3%) and 63 (37.3%)  
respectively have MS in the NCEP and the WHO 
groups (Tables 2 and 3). 
HDL criteria correctly diagnosed MS in 32 (67%) 
males and 182 (97%) females in the NCEP group 
while correctly diagnosing 4 (22.2%) males and 8 
(14.8%) females in the WHO group. TG criteria on 
the other hand correctly diagnosed 86.9% of males & 
42.5% of females in the NCEP group and 65.2% of 
males & 13.7% of females in the WHO group (Tables 
2 and 3), 
 Among those diagnosed as having MS, all three 
indices are strongly positively and significantly 
correlated (r=0.44-0.77; P=0.000) and with other 
metabolic indices. WC was most strongly positively 
correlated with FPG (r=0.560; P=0.000) in the NCEP 
category while WC was positively but not 
significantly correlated with FPG (r=0.254), systolic 
BP (r=0.480), and diastolic BP (r=0.490) in the WHO 
category (Table 6). ROC Analysis (Figures 1&2) 
show WC having the highest AUC value followed by 
WHR in the NCEP category while the WHR has the 
highest AUC value followed by WC in the WHO 




The multiplicity and variability of criteria for the 
diagnosis of MS as proposed by various expert 
groups working in different parts of the world have 
made the diagnosis controversial and complex. 
However, almost all working groups agree on the 
importance of visceral adiposity/central obesity and 
insulin resistance in the diagnosis of MS. Obesity is a 
rapidly growing health problem all over the world, 
conferring substantial excess risk for morbidity and 
mortality, especially from type 2 diabetes and 
atherosclerotic cardiovascular disease (CVD). 
The WHO and the NCEP-ATP III criteria were the 
only ones considered for the diagnosis of MS in this 
study because they are the only definitions easily 
applicable to the clinical setting while they also do 
not compulsorily require any of the three 
anthropometric indices studied to make a diagnosis.  
In this study, the overall prevalence of MS by the 
NCEP ATP-III criteria (36.7%) was significantly 
higher than by the WHO criteria (23.7%; p< 0.05). 
This finding is remarkably higher than envisaged and 
sharply contrasts with the findings of Fezeu et al 
(2007) who reported a prevalence of 7.9% in urban 
men in Cameroon using the WHO definition and a 
prevalence of <2% using the NCEP definition. This 
difference is observed in spite of the fact that both 
studies were conducted on adults within the sub-
Sahara African region and both studies employed 
both the WHO and NCEP criteria for the diagnosis of 
MS. However, there are some striking differences 
between this study and the Cameroonian study which 
may account for the observed incongruity. 
The Cameroonian study is general population based 
and recruited 1986 participants from both urban and 
rural communities around Yaounde, while the present 
study was conducted mainly on volunteers within two 
academic, communities of the University of Ibadan 
and the University College Hospital in Ibadan even 
though a few respondents were obtained from 
artisans, technicians and petty traders from adjoining 
areas outside both institutions; this may not be 
enough to make this study truly representative of the 
general population of inhabitants of Ibadan. 
Secondly, a considerable proportion (≈20%) of 
respondents in the Cameroonian study had no lipid 
profile results which necessitated their exclusion 
from the final analysis which may therefore not be a 
perfect reflection of population statistics. Some of 
those of those excluded may have diagnostic fasting 
lipid values which could possibly have increased the 
number of those diagnosed with MS by either/or both 
definitions. All parameters of interest were measured 
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in every participant in this study and all the 338 
participants have their data imputed into the final 
analysis making it representative of the studied 
population. 
Thirdly, a majority of the respondents in the 
Cameroonian study fall within the younger age 
groups and this may be responsible for the relatively 
low prevalence of MS reported in that study because 
the prevalence of MS increases with age. Another 
reason may be that the prevalence of MS found in 
either or both of the studies is artifactual because 
European cut off values were applied to Africans in 
making MS diagnosis, this is a result of non-
availability of ethnic specific values for sub-Saharan 
Africans (IDF, 2005). This on its own is capable of 
biasing the statistics in either or both studies. MS is 
diagnosed in other parts of the world using ethnic 
specific cut-off values for WC, WHR and BMI in the 
various definitions (IDF, 2005; Liu et al, 2006). 
This higher prevalence of MS using NCEP definition 
in this study agrees however with that of Kanjilal et 
al (2008) who did a similar study in India and made 
diagnosis of MS using several criteria which included 
the NCEP ATP III criteria and the WHO criteria. In 
their findings, the NCEP criteria predicted a 
significantly higher prevalence of MS than the WHO 
criteria among the Indian population. However, the 
respective MS prevalence of 36.7% & 23.7% found 
in this study are both lower than 40.3% and 30.6% 
found in the Indian population. The difference here 
may reflect ethnic and genetic differences between 
the populations studied but more importantly may be 
because of the differences in parameters used to 
arrive at MS diagnosis in the two populations. The 
recommended lower BMI cut-off for defining 
‘overweight’ in Asian Indians is 23 kg/m
2 
, modified 
WC measures is ≥94cm and ≥80cm and a waist–hip 
ratio (WHR) of 0.89 and 0.81 for men and women 
respectively (Kanjilal et al, 2008) while this study 
adopted European cut-off values (IDF, 2005). 
This study also found a prevalence rate of MS which 
is higher in women than in men in both diagnostic 
categories (table 1) which is in keeping with that of 
Ravalgia et al (2006) who studied the prevalence of 
MS among elderly Italians using NCEP criteria and 
found a higher prevalence in women (33.3%) than in 
men (19.6%) in 2006. However, this study recruited 
adults above 25years of age while the Italian study 
was conducted on elderly subjects aged 65 to 95 
years. This finding is however in contrast to that of 
Fezeu et al (2007) who in a similar study found the 
highest prevalence of MS in Urban men in 
Cameroon. This may be due to the differences in both 
studies as alluded to earlier. 
In this study, among those diagnosed with MS; WC 
was found to have statistically significant positive 
correlation with FPG and TG higher than those of 
WHR and BMI in the NCEP-ATP III category while 
WC shows strong positive but not statistically 
significant correlation with DBP, SBP and FPG 
higher than those for BMI and WHR in the WHO 
category. 
The most important finding in this study is from the 
ROC analysis of BMI, WHR and WC which shows 
that WC (with the highest AUC) is superior to both 
WHR and BMI in diagnosing MS using the NCEP 
criteria. ROC analysis also shows WC to be 
comparable with WHR and superior to BMI in the 
diagnosis of MS using WHO criteria (table 7). These 
findings are in keeping with those of Dobbelstein et 
al, (2001) who studied 9913 adult men and women 
selected among the participants of the Canadian Heart 
Health Survey which ended in 1992. This subgroup 
represents participants who have complete record of 
their WC, WHR and BMI. In their report, WC was 
also observed to have the largest AUC followed by 
WHR in an ROC analysis and concluded that WC 
may be the single best indicator of other individual 
and multiple CVD risk factors in adult Canadians. 
The superiority of WC to both BMI and WHR in the 
study discussed above is slightly different from the 
findings of Ryan et al, (2008) who compared WC and 
BMI in 402 Europeans and found BMI as useful as 
WC in identifying persons with MS
47
. The study by 
Ryan et al (2008) employed both IDF and ATP III 
criteria (while this study employed WHO instead of 
IDF) in the diagnosis of MS. Ryan et al did not 
employ ROC analysis to arrive at its conclusion as it 
is the case in this study. The Ryan’s study also did 
not include WHR in its analysis. 
This study and previous ones discussed above have 
all confirmed the reliability of WC as a predictor of 
metabolic risk. Incidentally, WC is the easiest of the 
obesity-related anthropometric parameters to measure 
because; (1) it involves a single parameter 
measurement of the waist while both BMI and WHR 
are indices derived from two different parameters, (2) 
it requires a simple, cheap and portable instrument 
(the non-stretch tape), (3) it requires less technical 
skill to measure, (4) respondents are more likely to co 
operate because it does not require the exposure of 
private body parts. These make WC more easily 
applicable to population screening studies while it 
can also be incorporated into routine general clinical 
physical examination at no additional cost to the 
patient. The limitation of WC as an anthropometric 
parameter lies in the non uniformity of its 
measurement method across working groups. 
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It is important to conduct separate studies in future to 
determine appropriate cut-off values for obesity 
indices (WC, WHR & BMI) that are consistent with 
metabolic and cardiovascular disease risk in sub-
saharan African populations. Applying such ethnic-
specific anthropometric cut-offs (which may differ 
from the currently applied European values) in 
diagnosing MS in these population will result in more 




Metabolic Syndrome prevalence may be high among 
apparently healthy Nigerians; WC is a cheap and 
reliable screening tool for metabolic syndrome. It is 
desirable to incorporate WC measurement into 
routine general clinical physical examination. It is 
important to determine appropriate WC cut off value 
for the diagnosis of Metabolic Syndrome in 
Nigerians. 
 It is important to determine the correlation 
between WC values derived in the same individuals 
using the various methods of WC measurement 
available, and to determine the correlation between 
the values obtained and visceral adiposity estimated 
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